These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 37145209)
1. Deregulated expression of polycomb repressive complex 2 target genes in a NF1 patient with microdeletion generating the RNF135-SUZ12 chimeric gene. Tritto V; Grilli F; Milani D; Riva P Neurogenetics; 2023 Jul; 24(3):181-188. PubMed ID: 37145209 [TBL] [Abstract][Full Text] [Related]
2. Identification of an atypical microdeletion generating the RNF135-SUZ12 chimeric gene and causing a position effect in an NF1 patient with overgrowth. Ferrari L; Scuvera G; Tucci A; Bianchessi D; Rusconi F; Menni F; Battaglioli E; Milani D; Riva P Hum Genet; 2017 Oct; 136(10):1329-1339. PubMed ID: 28776093 [TBL] [Abstract][Full Text] [Related]
3. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions. Mußotter T; Kluwe L; Högel J; Nguyen R; Cooper DN; Mautner VF; Kehrer-Sawatzki H BMC Med Genet; 2012 Oct; 13():98. PubMed ID: 23101500 [TBL] [Abstract][Full Text] [Related]
4. Mutations in RNF135, a gene within the NF1 microdeletion region, cause phenotypic abnormalities including overgrowth. Douglas J; Cilliers D; Coleman K; Tatton-Brown K; Barker K; Bernhard B; Burn J; Huson S; Josifova D; Lacombe D; Malik M; Mansour S; Reid E; Cormier-Daire V; Cole T; ; Rahman N Nat Genet; 2007 Aug; 39(8):963-5. PubMed ID: 17632510 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas. Steinmann K; Kluwe L; Friedrich RE; Mautner VF; Cooper DN; Kehrer-Sawatzki H J Invest Dermatol; 2009 Mar; 129(3):615-21. PubMed ID: 18800150 [TBL] [Abstract][Full Text] [Related]
15. Genetic/epigenetic effects in NF1 microdeletion syndrome: beyond the haploinsufficiency, looking at the contribution of not deleted genes. Tritto V; Bettinaglio P; Mangano E; Cesaretti C; Marasca F; Castronovo C; Bordoni R; Battaglia C; Saletti V; Ranzani V; Bodega B; Eoli M; Natacci F; Riva P Hum Genet; 2024 Jun; 143(6):775-795. PubMed ID: 38874808 [TBL] [Abstract][Full Text] [Related]
16. Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197 [TBL] [Abstract][Full Text] [Related]
17. Identification of genes potentially involved in the increased risk of malignancy in NF1-microdeleted patients. Pasmant E; Masliah-Planchon J; Lévy P; Laurendeau I; Ortonne N; Parfait B; Valeyrie-Allanore L; Leroy K; Wolkenstein P; Vidaud M; Vidaud D; Bièche I Mol Med; 2011; 17(1-2):79-87. PubMed ID: 20844836 [TBL] [Abstract][Full Text] [Related]
18. The polycomb repressive complex 2 is a potential target of SUMO modifications. Riising EM; Boggio R; Chiocca S; Helin K; Pasini D PLoS One; 2008 Jul; 3(7):e2704. PubMed ID: 18628979 [TBL] [Abstract][Full Text] [Related]
19. Type 2 NF1 deletions are highly unusual by virtue of the absence of nonallelic homologous recombination hotspots and an apparent preference for female mitotic recombination. Steinmann K; Cooper DN; Kluwe L; Chuzhanova NA; Senger C; Serra E; Lazaro C; Gilaberte M; Wimmer K; Mautner VF; Kehrer-Sawatzki H Am J Hum Genet; 2007 Dec; 81(6):1201-20. PubMed ID: 17999360 [TBL] [Abstract][Full Text] [Related]
20. Expression analysis of genes lying in the NF1 microdeletion interval points to four candidate modifiers for neurofibroma formation. Bartelt-Kirbach B; Wuepping M; Dodrimont-Lattke M; Kaufmann D Neurogenetics; 2009 Feb; 10(1):79-85. PubMed ID: 18850118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]